Related Experiment Video

Updated: May 19, 2026

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis
10:40

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis

Published on: April 25, 2022

MicroRNAs in genetic disease: rethinking the dosage

Alexandra Henrion-Caude1, Muriel Girard, Jeanne Amiel

  • 1Inserm U-Institut IMAGINE, Hôpital Necker-Enfants Malades, Paris, France. alexandra.caude@inserm.fr

Current Gene Therapy
|August 4, 2012
PubMed

Insights

Mutations in microRNAs (miRNAs), not just protein-coding genes, significantly impact genetic diseases. Understanding miRNA roles is crucial for developing effective miRNA-based gene therapies.

Area of Science:

  • Genetics
  • Molecular Biology
  • Epigenetics

Background:

  • Historically, genetic mutation research focused primarily on protein-coding genes.
  • The role of non-coding genetic elements, such as microRNAs (miRNAs), in disease has been underappreciated.
  • miRNAs are critical regulators of gene expression, acting as phenotypic modulators and genetic switches.

Purpose of the Study:

  • To delineate the contribution of microRNA (miRNA) mutations to genetic diseases.
  • To establish a framework for developing miRNA-based therapeutic strategies, focusing on dosage.
  • To explore the role of miRNAs in epigenetics and their inheritance patterns in human diseases.

Main Methods:

  • Review and categorization of human diseases associated with miRNA alterations.
  • Analysis of miRNA function in gain-of-function and loss-of-function scenarios.
  • Investigation of de novo and inherited miRNA mutations (Mendelian and epistatic traits).

Main Results:

  • Identified diverse roles of miRNAs in modulating phenotypes, regulating gene expression, and acting as genetic switches.
  • Demonstrated that both gain and loss of miRNA function necessitate specific therapeutic interventions (antagonization or supply).
  • Categorized human diseases based on miRNA alteration types, revealing their involvement in epigenetic regulation.

Conclusions:

  • MicroRNA mutations play a significant role in genetic diseases, challenging the traditional focus on protein-coding genes.
  • A comprehensive understanding of miRNA contributions to disease is essential for advancing gene therapy strategies.
  • Targeting miRNAs offers a promising avenue for novel therapeutic approaches, particularly in managing dosage for effective treatment.

More Related Videos

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method09:06

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method

Published on: October 7, 2025

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...